A Phase 3 interventional study of Abemaciclib and Standard Adjuvant Endocrine Therapy in Breast Cancer, sponsored by Eli Lilly and Company. Active, not recruiting at 619 sites in 38 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-24.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies testing abemaciclib in Breast Neoplasms — 22 open to participants now, 34 under way, 10 of them phase 3. abemaciclib · Breast Neoplasms.
Among the 55 studies testing abemaciclib in Breast Neoplasms, this one has the largest enrollment, is one of 3 that started in 2017, is one of 11 in phase 3, reaches primary completion later than 4 of the 33 other live ones, and was the 13th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →22 of the 55 studies testing abemaciclib in Breast Neoplasms are open now, in 6 countries. Recruiting first, the newest first:
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 18+
UNC Lineberger Comprehensive Cancer Center · Sites in United States
Ages 18+
Japanese Foundation for Cancer Research · Sites in Japan
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Mridula George, MD · Sites in United States
Ages 60+ · Women only
By country, each count listing its studies:
abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, abemaciclib is the treatment under test here. Read study by study →
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 29 · Phase 3 11 · Phase 4 8
First in 2014; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5,637 is above the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 120 across the 55 interventional studies. Of the 17 that completed or were terminated, 12 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 55 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
88 studies in Breast Neoplasms by Eli Lilly and Company: 7 open now, 22 under way, 8 of them phase 3. Of 61 finished, 40 (66%) have results posted.
Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, this one is the 3rd largest by enrollment of the 80 interventional ones that give a count, is one of 3 that started in 2017, is one of 16 in phase 3, reaches primary completion later than 4 of the 21 other live ones, and was the 63rd registered.
Eli Lilly and Company’s Breast Neoplasms studies by the year they started, since 1998.
6 of the studies testing abemaciclib in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06341621Phase 3Fudan UniversityChemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib | 2027-02-25 |
| NCT05305924The Methodist Hospital Research InstituteFulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer | 2026-12-01 |
| NCT06207734Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestDiscontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer | 2027-01-10 |
| NCT04614194University of Texas Southwestern Medical CenterSingle Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib | 2027-04-15 |
| NCT04305834City of Hope Medical CenterAbemaciclib and Endocrine Therapy in Older Patients With Breast Cancer. | 2027-05-21 |
Add all 6 to your calendar (.ics) → With an account.
Among the 55 studies testing abemaciclib in Breast Neoplasms, from their registry updates:
Among Eli Lilly and Company’s 88 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Pathologic lymph node involvement and at least one of the following indicating a higher risk of recurrence:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received Abemaciclib orally at 150 milligrams (mg) twice daily with at least 6 hours between doses for up to 2 years or until evidence of disease recurrence or other discontinuation criteria were met, whichever occurs first. Endocrine therapy (physicians' choice) standard-of-care was administered according to package label until discontinuation criteria were met.
Drug: Abemaciclib · Drug: Standard Adjuvant Endocrine Therapy
Endocrine therapy (physicians' choice) standard-of-care was administered according to package label until discontinuation criteria were met.
Drug: Standard Adjuvant Endocrine Therapy
Administered orally.
Also known as: LY2835219
Administered according to label instructions.
Invasive Disease Free Survival (IDFS)
IDFS, as defined by the STEEP System, was measured from the date of randomization to the date of first occurrence of one of the following events: ipsilateral invasive breast tumor recurrence, regional invasive breast cancer recurrence, distant recurrence, contralateral invasive breast cancer, second primary non-breast invasive cancer, death attributable to any cause.
Time frame: Baseline to Recurrence or Death from Any Cause (Up to 32 Months)
IDFS for Participants With Ki-67 Index ≥20%
Outcome data will be provided after the study is completed.
Time frame: Baseline to Recurrence or Death from Any Cause (Approximately 10 Years)
Distant Relapse-Free Survival (DRFS)
Distant relapse-free survival is defined as the time from randomization to distant recurrence or death from any cause, whichever occurs first.
Time frame: Baseline to Distant Recurrence or Death from Any Cause (Up to 32 Months)
Overall Survival (OS)
Outcome data will be provided after the study is completed.
Time frame: Baseline to Death from Any Cause (Approximately 10 Years)
Pharmacokinetics (PK): Minimum Steady State Concentration (Cmin,ss) of Abemaciclib
Pharmacokinetics (PK): Minimum Steady State Concentration (Cmin,ss) of Abemaciclib
Time frame: Day 1 (2 hours post-dose), Days 30, 60, 90 post-dose
Change From Baseline on the Functional Assessment of Cancer Therapy - Breast (FACT-B)
Outcome data will be provided after the study is completed.
Time frame: Baseline, Follow Up (Approximately 3 Years)
Change From Baseline on the Functional Assessment of Cancer Therapy - Endocrine Symptoms (FACT-ES)
Outcome data will be provided after the study is completed.
Time frame: Baseline, Follow Up (Approximately 3 Years)]
Change From Baseline on the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F)
Outcome data will be provided after the study is completed.
Time frame: Baseline, Follow Up (Approximately 3 Years)]
Change From Baseline on the EuroQol Five-Dimension Five-Level Questionnaire (EQ-5D-5L)
Outcome data will be provided after the study is completed.
Time frame: Baseline, Follow Up (Approximately 3 Years)]
Completers included participants who had recurrence disease, death due to any cause, and participants off treatment but on study follow-up.
| Milestone | 150 mg Abemaciclib + Endocrine Therapy | Endocrine Therapy |
|---|---|---|
| Started | 2808 | 2829 |
| Received at least one dose of study drug | 2791 | 2800 |
| Completed | 650 | 607 |
| Not completed | 2158 | 2222 |
| Withdrew: Withdrawal by subject | 119 | 134 |
| Withdrew: Lost to follow-up | 12 | 13 |
| Withdrew: Missing disposition data | 0 | 1 |
| Withdrew: On study treatment | 2027 | 2074 |
IDFS, as defined by the STEEP System, was measured from the date of randomization to the date of first occurrence of one of the following events: ipsilateral invasive breast tumor recurrence, regional invasive breast cancer recurrence, distant recurrence, contralateral invasive breast cancer, second primary non-breast invasive cancer, death attributable to any cause.
| Months | 150 mg Abemaciclib + Endocrine Therapy | Endocrine Therapy |
|---|---|---|
| Invasive Disease Free Survival (IDFS) | NA (NA to NA) | NA (NA to NA) |
Outcome data will be provided after the study is completed.
Results for this outcome have not been posted.
Distant relapse-free survival is defined as the time from randomization to distant recurrence or death from any cause, whichever occurs first.
| Months | 150 mg Abemaciclib + Endocrine Therapy | Endocrine Therapy |
|---|---|---|
| Distant Relapse-Free Survival (DRFS) | NA (NA to NA) | NA (NA to NA) |
Outcome data will be provided after the study is completed.
Results for this outcome have not been posted.
Pharmacokinetics (PK): Minimum Steady State Concentration (Cmin,ss) of Abemaciclib
| Nanograms per milliliter (ng/mL) | 150 mg Abemaciclib + Endocrine Therapy |
|---|---|
| Pharmacokinetics (PK): Minimum Steady State Concentration (Cmin,ss) of Abemaciclib | 143 ± 110 |
Outcome data will be provided after the study is completed.
Results for this outcome have not been posted.
Outcome data will be provided after the study is completed.
Results for this outcome have not been posted.
Outcome data will be provided after the study is completed.
Results for this outcome have not been posted.
Outcome data will be provided after the study is completed.
Results for this outcome have not been posted.
Collected over Baseline to 32 Months. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 150 mg Abemaciclib + Endocrine Therapy | 38/2,791 (1.4%) | 344/2,791 (12.3%) | 2,723/2,791 (97.6%) |
| Endocrine Therapy | 36/2,800 (1.3%) | 202/2,800 (7.2%) | 2,318/2,800 (82.8%) |
| Event | 150 mg Abemaciclib + Endocrine Therapy | Endocrine Therapy |
|---|---|---|
| PneumoniaInfections and infestations | 23/2791 | 14/2800 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 16/2791 | 3/2800 |
| Deep vein thrombosisVascular disorders | 16/2791 | 3/2800 |
| DiarrhoeaGastrointestinal disorders | 15/2791 | 0/2800 |
| Urinary tract infectionInfections and infestations | 12/2791 | 4/2800 |
| CellulitisInfections and infestations | 11/2791 | 9/2800 |
| CholecystitisHepatobiliary disorders | 10/2791 | 2/2800 |
| AnaemiaBlood and lymphatic system disorders | 8/2791 | 2/2800 |
| PyrexiaGeneral disorders | 7/2791 | 0/2800 |
| InfluenzaInfections and infestations | 7/2791 | 3/2800 |
| Event | 150 mg Abemaciclib + Endocrine Therapy | Endocrine Therapy |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 2294/2791 | 199/2800 |
| NeutropeniaBlood and lymphatic system disorders | 1246/2791 | 140/2800 |
| FatigueGeneral disorders | 1073/2791 | 433/2800 |
| LeukopeniaBlood and lymphatic system disorders | 1026/2791 | 171/2800 |
| Abdominal painGastrointestinal disorders | 945/2791 | 226/2800 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 571/2791 | 876/2800 |
| NauseaGastrointestinal disorders | 779/2791 | 222/2800 |
| AnaemiaBlood and lymphatic system disorders | 634/2791 | 88/2800 |
| Hot flushVascular disorders | 393/2791 | 587/2800 |
| HeadacheNervous system disorders | 482/2791 | 359/2800 |
All randomized participants.
| Age, Continuous(years) | 150 mg Abemaciclib + Endocrine Therapy | Endocrine Therapy | Total |
|---|---|---|---|
| Mean | 52.20 ± 11.26 | 52.10 ± 11.20 | 52.10 ± 11.23 |
| Sex: Female, Male(Participants) | 150 mg Abemaciclib + Endocrine Therapy | Endocrine Therapy | Total |
|---|---|---|---|
| Female | 2787 | 2814 | 5601 |
| Male | 21 | 15 | 36 |
| Ethnicity (NIH/OMB)(Participants) | 150 mg Abemaciclib + Endocrine Therapy | Endocrine Therapy | Total |
|---|---|---|---|
| Hispanic or Latino | 355 | 378 | 733 |
| Not Hispanic or Latino | 1734 | 1738 | 3472 |
| Unknown or Not Reported | 719 | 713 | 1432 |
| Race (NIH/OMB)(Participants) | 150 mg Abemaciclib + Endocrine Therapy | Endocrine Therapy | Total |
|---|---|---|---|
| American Indian or Alaska Native | 64 | 58 | 122 |
| Asian | 675 | 669 | 1344 |
| Native Hawaiian or Other Pacific Islander | 3 | 4 | 7 |
| Black or African American | 57 | 53 | 110 |
| White | 1947 | 1978 | 3925 |
| More than one race | 22 | 25 | 47 |
| Unknown or Not Reported | 40 | 42 | 82 |
| Region of Enrollment(Participants) | 150 mg Abemaciclib + Endocrine Therapy | Endocrine Therapy | Total |
|---|---|---|---|
| Argentina | 77 | 68 | 145 |
| Australia | 108 | 109 | 217 |
| Austria | 22 | 20 | 42 |
| Belgium | 65 | 51 | 116 |
| Brazil | 144 | 153 | 297 |
| Canada | 28 | 16 | 44 |
| China | 187 | 170 | 357 |
| Czechia | 15 | 12 | 27 |
| Denmark | 54 | 58 | 112 |
| Finland | 45 | 49 | 94 |
| France | 86 | 101 | 187 |
| Germany | 148 | 152 | 300 |
| Greece | 74 | 64 | 138 |
| Hong Kong | 8 | 12 | 20 |
| Hungary | 24 | 28 | 52 |
| India | 59 | 53 | 112 |
| Israel | 39 | 38 | 77 |
| Italy | 72 | 59 | 131 |
| Japan | 181 | 196 | 377 |
| Mexico | 104 | 121 | 225 |
| Netherlands | 5 | 14 | 19 |
| New Zealand | 21 | 22 | 43 |
| Poland | 65 | 60 | 125 |
| Portugal | 21 | 16 | 37 |
| Puerto Rico | 1 | 3 | 4 |
| Romania | 53 | 60 | 113 |
| Russia | 66 | 73 | 139 |
| Saudi Arabia | 5 | 9 | 14 |
| Singapore | 11 | 21 | 32 |
| South Africa | 3 | 6 | 9 |
| South Korea | 122 | 123 | 245 |
| Spain | 144 | 148 | 292 |
| Sweden | 7 | 5 | 12 |
| Taiwan | 64 | 60 | 124 |
| Turkey | 125 | 110 | 235 |
| Ukraine | 54 | 51 | 105 |
| United Kingdom | 99 | 100 | 199 |
| United States | 402 | 418 | 820 |
Showing the first 100 of 619 sites across 38 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jul 2017 to primary completion in Mar 2020, 32 months.
Results were first posted in Apr 2021, 1 year after primary completion.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 32 months is below that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abemaciclib